Published January 1, 2024 | Version v1
Journal article Open

Advanced protein-embedded bimetallic nanocomposite optimized for in vivo fluorescence and magnetic resonance bimodal imaging

  • 1. Department of Experimental Physics, Faculty of Science, Palacký University Olomouc, tř. 17. listopadu 12, 77900 Olomouc, Czech Republic
  • 2. Institut klinicke a experimentalni mediciny
  • 3. Department of Analytical Chemistry, Faculty of Science, Palacký University Olomouc, tř. 17. listopadu 12, 77900 Olomouc, Czech Republic
  • 4. Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Šlechtitelů 27, 77900 Olomouc, Czech Republic

Description

Hypothesis: The development of bimodal imaging probes represents a hot topic of current research. Herein, we deal with developing an innovative bimodal contrast agent enabling fluorescence imaging (FI)/magnetic resonance imaging (MRI) and, simultaneously, consisting of biocompatible nanostructures. Optimized synthesis of advanced protein-embedded bimetallic (APEBM) nanocomposite containing luminescent gold nanoclusters (AuNC) and superparamagnetic iron oxide nanoparticles (SPION), suitable for in vivo dual-modal FI/MR imaging is reported. Experiments: The APEBM nanocomposite was prepared by a specific sequential one-pot green synthetic approach that is optimized to increase metals (Au, Fe) content and, consequently, the imaging ability of the resulting nanostructures. The protein matrix, represented by serum albumin, was intentionally chosen, and used since it creates an efficient protein corona for both types of optically/magnetically-susceptible nanostructures (AuNC, SPION) and ensures biocompatibility of the resulting APEBM nanocomposite although it contains elevated metal concentrations (approx. 1 mg?mL?1 of Au, around 0.3 mg?mL?1 of Fe). In vitro and in vivo imaging was performed. Findings: Successful in vivo FI and MRI recorded in healthy mice corroborated the applicability of the APEBM nanocomposite and, simultaneously, served as a proof of concept concerning the potential future exploitation of this new FI/MRI bimodal contrast agent in preclinical and clinical practice.

Notes

Financial support by the Czech Science Foundation (project no. 19-03207S), from the Ministry of Health CR-DRO (Institute for Clinical and Experimental Medicine IKEM, IN00023001), from the project National Institute for Research of Metabolic and Cardiovascular Diseases (Programme EXCELES, Project no. LX22NPO5104) - Funded by the European Union - Next Generation EU and by the Internal Grant Agency of Palacký University (projects no. IGA_PrF_2023_003) is gratefully acknowledged. Veronika Svačinová is acknowledged for tests of robustness and reproducibility of the newly developed synthetic approach; Vítězslav Heger is thanked for the verification of purity of BSA by using EDS and XRD; Jitka Prachařová is acknowledged for enabling samples drying; Marcela Václavíková is thanked for her help with several articles (not available via our institutional account) retrieval, Marie Kvasnicová is thanked for tests in HeLa cancer cells, and Martin Mistrík is acknowledged for healthy RPE-1 cell line donation.

Files

1-s2.0-S002197972400359X-main.pdf

Files (8.0 MB)

Name Size Download all
md5:5cdaf6aa01888bb131bda8553681299b
8.0 MB Preview Download

Additional details

Related works

Has metadata
38422973 (PMID)
Is part of
0021-9797 (ISSN)
1095-7103 (ISSN)
References
10.1016/j.jcis.2024.02.116 (DOI)